MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1186/s12896-025-00993-3

Медицинская библиотека · BMC biotechnology · 2025

An engineered hypoxia-response promoter for human umbilical cord-derived mesenchymal stem cell-based therapeutics.

Yang Song, Zhuang Weizhong, Zhou Lishi, Kong Weiwei, Zou Wanwan, Zhu Qikun, Bian Enze, Lin Bin, Cen Jianzheng, Gao Qiang, Chen Jimei

СтатьяПеревод в очереди

Аннотация

Myocardial infarction, characterized by insufficient blood supply to the heart, leads to ischemia and hypoxia of myocardial tissues, causing injury and decreased cardiac function. Despite improvements in pharmaceutical and interventional therapies, it remains a leading cause of death worldwide. Human umbilical cord mesenchymal stem cells (hUC-MSCs) play an important role in the repair of infarcted myocardium by promoting angiogenesis, reducing inflammation, secreting growth factors and cytokines. However, the harsh hypoxic microenvironment of infarcted myocardial tissue poses a threat to the survival and function of transplanted hUC-MSCs. In this study, we modified the candidate gene promoter of hUC-MSCs under hypoxic conditions and created a promoter that can respond quickly under hypoxic conditions. We found that the modified promoter significantly promoted the transcription efficiency as hypoxia time increased. This indicates that the engineered hypoxia-response promoter can effectively drive gene expression in a hypoxic environment. Furthermore, the transcription efficiency of the modified promoter under normoxic conditions is lower than that of common promoters in eukaryotic organisms, suggesting that this effect can improve the efficacy and safety of hUC-MSC-based myocardial infarction treatment by ensuring that cells function effectively in the damaged hypoxic area.

Для цитирования: Yang Song, Zhuang Weizhong, Zhou Lishi, Kong Weiwei, Zou Wanwan, Zhu Qikun, Bian Enze, Lin Bin, Cen Jianzheng, Gao Qiang, Chen Jimei. An engineered hypoxia-response promoter for human umbilical cord-derived mesenchymal stem cell-based therapeutics.. BMC biotechnology. 2025. DOI: 10.1186/s12896-025-00993-3.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.